IceCure Medical Ltd (NASDAQ:ICCM – Free Report) – HC Wainwright upped their FY2023 earnings per share (EPS) estimates for shares of IceCure Medical in a report issued on Thursday, November 16th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.34) per share for the year, up from their prior estimate of ($0.35). HC Wainwright currently has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for IceCure Medical’s current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for IceCure Medical’s Q4 2023 earnings at ($0.08) EPS, Q3 2024 earnings at ($0.08) EPS, Q4 2024 earnings at ($0.08) EPS and FY2024 earnings at ($0.32) EPS.
Separately, Alliance Global Partners dropped their price objective on IceCure Medical from $4.25 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, August 15th.
IceCure Medical Trading Up 2.7 %
NASDAQ ICCM opened at $0.74 on Monday. The business’s 50-day moving average price is $0.82 and its two-hundred day moving average price is $1.03. IceCure Medical has a 12 month low of $0.52 and a 12 month high of $4.73. The firm has a market capitalization of $33.76 million, a PE ratio of -2.00 and a beta of 0.23. The company has a current ratio of 5.30, a quick ratio of 4.59 and a debt-to-equity ratio of 0.02.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of America Corp DE raised its stake in IceCure Medical by 57.2% during the 4th quarter. Bank of America Corp DE now owns 55,388 shares of the company’s stock worth $86,000 after buying an additional 20,159 shares during the period. JPMorgan Chase & Co. acquired a new position in IceCure Medical during the 2nd quarter worth approximately $78,000. Boothbay Fund Management LLC raised its stake in IceCure Medical by 100.0% during the 4th quarter. Boothbay Fund Management LLC now owns 40,000 shares of the company’s stock worth $62,000 after buying an additional 20,000 shares during the period. Finally, UBS Group AG increased its holdings in IceCure Medical by 1,302.3% during the 4th quarter. UBS Group AG now owns 28,986 shares of the company’s stock worth $45,000 after purchasing an additional 26,919 shares in the last quarter. 0.34% of the stock is owned by institutional investors and hedge funds.
IceCure Medical Company Profile
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
- Five stocks we like better than IceCure Medical
- What Does a Stock Split Mean?
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- MarketBeat Week in Review – 11/13 – 11/17
- How to Invest in the FAANG Stocks
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.